Press release

Dexcom Reports Second Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022. Second Quarter

articleDexcom, Inc.July 28, 20223/company/dexcom-inc/news/dexcom-reports-second-quarter-2022-financial-results-2022-07-28
Dexcom Reports Second Quarter 2022 Financial Results

About this update from Dexcom, Inc.

[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022.\n\nSecond Quarter 2022 Financial Highlights:\n\n\nRevenue grew 17% versus the same quarter of the prior year to $696.2 million on a reported basis and 16% on an organic1 basis.\n\n\nU.S. revenue growth of 11% and international revenue growth of 39% on a reported basis. International revenue growth was 34% on an organic1 basis.\n\n\nGAAP operating income of $77.0 million or 11.1% of revenue, a decrease of 590 basis points compared to the second quarter of 2021. Non-GAAP operating income* of $101.9 million or 14.6% of revenue, a decrease of 250 basis points compared with the same quarter of the prior year.\n\n\nStrategic Highlights:\n\n\nAdvanced CGM portfolio strategy, including the launches of Dexcom ONE in the UK and Spain.\n\n\nShowcased the present and future potential of CGM technology with a robust research presence at the Advanced Technologies and Treatments for Diabetes (ATTD) and American Diabetes Association (ADA) conferences.\n\n\nReceived CE Mark for an updated sensor algorithm, making the latest G7 sensor technology available to international markets.\n\n\nSubsequent to the end of the quarter, launched the Dexcom G6 mobile app in Spanish, providing more choice to users and eliminating a potential language barrier to optimal care.\n\n\n“In the second quarter, Dexcom advanced a number of key initiatives, including the expansion of our CGM portfolio strategy in international markets,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We are excited for the rest of this year, particularly as we implement a broader launch of G7 in the coming weeks.”\n\n2022 Annual Guidance\n\nThe company is updating fiscal year 2022 revenue guidance, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:\n\n\nRevenue of approximately $2.86 - 2.91 billion (17-19% growth)\n\n\nNon-GAAP Gross Profit Margin of approximately 65%\n\n\nNon-GAAP Operating Margin of approximately 16%\n\n\nAdjusted EBITDA Margin of approximately 25%\n\n\nSecond Quarter 2022 Financial Results\n\nRevenue: In the second quarter of 2022, worldwide revenue grew 17% to $696.2 million, up from $595.1 million in the second quarter of 2021. Volu...

More updates from Dexcom, Inc.